Company: Nina Capital
Founder and Managing Partner: Dr Marta G. Zanchi
Website: https://www.nina.capital
About Nina Capital
Founded in 2019, Nina Capital is a specialised healthtech venture capital firm based in Spain and the U.S. It accelerates innovation in global healthcare via its investments into over 50 early stage startups across three funds, with its most recent fund III launching at the beginning of 2025.
Nina Capital has an international mandate and a truly global impact on the healthtech sector with portfolio companies spanning 18 countries and 4 continents, and their team representing 12 nationalities. Dr Marta G. Zanchi, Founder and Managing Partner was previously a member of the faculty at the Stanford School of Medicine and founding director of the digital health programs at Stanford Biodesign, for which she continues to be an ambassador. As a distinguishing factor in its DNA, Nina Capital incorporates need-based and data-driven Biodesign processes into its approach to making and managing investments. Dr. Zanchi was also the founding CEO of RenovoRX, a Nasdaq-listed medtech company, and leverages her founding and operational expertise to support Nina Capital’s companies.
Nina Capital specialises in startups that manage patient data and develop innovative, information technology-enabled medical devices, and is at the forefront of AI integration into healthcare to provide better patient outcomes. Investing into this sector across multiple countries provides a unique challenge due to how regulations around medical data sharing differ country to country.
Nina Capital’s portfolio companies Mindpeak and Magentiq Eye are using AI to assist pathologists and endoscopists with tools that combine strong financial incentives for adoption by their enterprise partners with meaningful downstream patient outcomes. Sonar Mental Health is a platform that assists students through a combination of AI and human-led support. Methinks AI allows real-time stroke triage through AI-based neuroimaging interpretation, a first of its kind solution that is already cleared by the FDA. Promptly Health has been selected for an NHS Wales-wide initiative to lead their Real World Evidence agenda.
Nina Capital opened its US office in Palo Alto, California, this year. Located just outside Stanford University, where Nina Capital originated, the new U.S. base strengthens Nina Capital’s on-the-ground presence in the world’s largest healthtech market. The firm’s presence on both continents allows it to support portfolio companies – bringing strategic guidance, cross-market perspective, and access to key decision-makers to a growing portfolio of international companies.
